Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 10 March 2025, 19:24 HKT/SGT
Share:
    

Source: Eisai
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time

TOKYO, Mar 10, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been recognized as the 2025 KENKO Investment for Health by Japan’s Ministry of Economy, Trade, and Industry (METI) and the Tokyo Stock Exchange, for the first time as a company strategically carrying out efforts with regard to its employees' health from a management perspective. Eisai has also been certified as an Outstanding Organization of KENKO Investment for Health Program in the large enterprise category (White 500) by METI and the Nippon Kenko Kaigi for the sixth time.

The Outstanding Organizations of KENKO Investment for Health Program recognizes outstanding large enterprises, and small and medium-sized enterprises engaging in efforts for health and productivity management by evaluating from a business-management perspective based on the following criteria: “management principles and policies”, “organized structure”, “implementation of systems and measures”, and “evaluation and improvement”. Among the organizations certified as Outstanding Organizations of KENKO Investment for Health, the top 500 in the large enterprise category are recognized as “White 500”. Eisai exceeded the industry average in all criteria, receiving particularly high evaluations in areas such as “information disclosure and dissemination to other companies” (management principles and policies), “lifestyle improvement of employees” and “laying the foundation for the practice of health management” (implementation of systems and measures). The KENKO Investment for Health recognizes outstanding publicly listed companies that are excellent in practicing health management, among companies certified as Outstanding Organizations of KENKO Investment for Health Program. In 2025, 53 companies, including Eisai, were selected from the 3,869 companies that responded to the “Survey on KENKO Investment for Health.”

Eisai’s corporate concept is to give first thought to patients and the people in the daily living domain, increasing the benefits that health care provides to them as well as meet their diverse healthcare needs worldwide. Eisai calls this the “human health care (hhc)” concept. Eisai regards its employees as an important stakeholder and asset for the realization of its hhc concept.

Eisai issued the Eisai Health Declaration in 2019, and has been making efforts to promote health management. Moreover, to increase human capital value, Eisai made a partial amendment to the Articles of Incorporation at an Ordinary General Meeting of Shareholders in 2022, clearly stating that it will strive to “ensure stable employment”, “respect human rights and diversity”, “provide full opportunities for growth to support self-fulfillment”, and “create an employee-friendly environment”. Eisai has also reinforced its human resource initiatives, including the formulation of an Integrated Human Resource Strategy, with the pillars of “wellbeing, including health, of employees”, “diverse work style”, “development and growth of employees”, and “growth of the organization and businesses”. Since 2023, Eisai has been promoting proactive information disclosure with its Human Capital Report which summarizes Eisai’s human capital initiatives and KPIs linked to its human resource strategies.

Through promoting health and productivity management and increasing human capital value, Eisai will continue to increase non-financial value and further contribute to increasing the benefits of patients and the people in the daily living domain.

Media Inquiries:
Public Relations Department, Eisai Co., Ltd.
+81-(0)3-3817-5120




Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 31, 2025 17:27 HKT/SGT
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31, 2025 08:30 HKT/SGT
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
July 31, 2025 08:20 HKT/SGT
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
July 31, 2025 08:10 HKT/SGT
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
July 29, 2025 08:01 HKT/SGT
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
July 25, 2025 12:31 HKT/SGT
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
July 23, 2025 09:07 HKT/SGT
Launch of Beova(R) Tablets in Thailand for Overactive Bladder
July 22, 2025 10:56 HKT/SGT
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025
July 16, 2025 13:50 HKT/SGT
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
July 14, 2025 09:20 HKT/SGT
"URECE" (Dotinurad) Launched in China as a treatment for Gout
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: